Alise Reicin, MD, is Senior Vice President, Head of Global Clinical Development, for the biopharmaceutical business of Merck KGAa, Darmstadt Germany. In this capacity, she oversees Clinical Therapeutic Areas, Statistics, Evidence and Value Development and Clinical Operations. Dr. Reicin has extensive early and late clinical development experience working across a broad range of therapeutic areas including oncology and immunology. Dr. Reicin is an accomplished pharmaceutical executive with strong leadership ability, having served as a Vice President in various capacities across R&D at MSD (Merck Sharp & Dohme) in the decade prior to taking on her current position.
In her past positions, Dr. Reicin has served as Vice President, Project and Pipeline Leadership, Oncology Franchise at MSD. In this capacity, her impact on the cancer research field was significant. She led MSD's PD-1 program and oversaw the initial development and filing activities worldwide, including the first approval in the US and the creation and initiation of early and late stage development plans in several different indications including Melanoma, NSCLC, Gastric Cancer, Breast Cancer, Urothelial Cancer, Hodgkins Lymphoma, Head and Neck Cancer. She also managed program leaders across early and late oncology product development teams. During Dr. Reicin’s tenure at MSD, she held roles of increasing responsibility in R&D, including Vice President and Therapeutic Area Head (Bone, Respiratory, Immunology and Endocrinology); Vice President, Research & Early Development (Bone, Respiratory, Immunology and Endocrinology Franchise Integrator); Vice President, Strategic Realization Office; Vice President and Therapeutic Area Head (Clinical Immunology & Analgesia); and Head of a Transformation Task Force for late clinical development.
Prior to her positions at MSD, Dr. Reicin was a faculty member at Columbia Medical School, New York, NY, and a physician and researcher at Columbia Presbyterian Hospital, New York, NY. She has a degree in biochemistry from Barnard College of Columbia University and received her medical degree from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with Massachusetts Institute of Technology (MIT).